Aoxing Pharmaceutical Company Inc. Receives Notice of Extension From NYSE MKT LLC

JERSEY CITY, NJ--(Marketwired - January 15, 2014) - Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) (“Aoxing Pharma”), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, announced on October 30, 2013 that it had received notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma’s Annual Report on Form 10-K for the year ended June 30, 2013, Aoxing Pharma is not in compliance with Section 1003(a)(iii) of the NYSE MKT Company Guide since it reported stockholders’ equity of less than $6,000,000 at June 30, 2013 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years then ended. On December 4, 2013, Aoxing Pharma announced that it had received additional notice from NYSE MKT LLC that, based upon the financial statements contained in Aoxing Pharma’s Quarterly Report on Form 10-Q for the period ended September 30, 2013, it is also not in compliance with Section 1003(a)(ii) of the Company Guide since it reported stockholders’ equity of less than $4,000,000 at September 30, 2013 and has incurred losses from continuing operations and/or net losses in three of its four most recent fiscal years ended June 30, 2013.

The Company was afforded the opportunity to submit a plan of compliance to the Exchange. On November 25, 2013 the Company presented its plan of compliance with Section 1003(a)(iii) and on December 26, 2013 the Company presented supplemental material as its plan of compliance with Section 1003(a)(ii). On January 10, 2014 the Exchange notified the Company that it accepted the Company’s plan of compliance with Section 1003(a)(ii) and Section 1003(a)(iii) and granted the Company an extension until April 27, 2015 to regain compliance with Sections 1003(a)(ii) and 1003(a)(iii). The Company will be subject to periodic review by the Exchange Staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with Sections 1003(a)(ii) and (1003(a)(iii) by the end of the extension period could result in the Company being delisted from the NYSE MKT LLC.

The Company’s plan of compliance with Sections 1003(a)(ii) and 1003(a)(iii) are supplemental to, and not in lieu of, the Company’s plan of compliance with Section 1003(a)(iv) of the Company Guide, which Aoxing Pharma submitted to NYSE MKT LLC in response to its notice that Aoxing Pharma is not in compliance with Section 1003(a)(iv) of the Company Guide since it has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it appears questionable, in the opinion of the NYSE MKT, as to whether the Company will be able to continue operations and/or meet its obligations as they mature. On December 3, 2013 the Exchange notified the Company that it accepted the Company’s plan of compliance with Section 1003(a)(iv) and granted the Company an extension until March 1, 2014 to regain compliance with Section 1003(a)(iv). Failure to make progress consistent with the plan or to regain compliance with Section 1003(a)(iv) by March 1, 2014 could result in the Company being delisted from the NYSE MKT LLC, notwithstanding the Company’s ongoing progress in achieving compliance with Sections 1003(a)(ii) and 1003(a)(iii).

About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). Aoxing Pharma has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. For more information, please visit: www.aoxingpharma.com.